<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774124</url>
  </required_header>
  <id_info>
    <org_study_id>071694</org_study_id>
    <secondary_id>1R21DK071694</secondary_id>
    <nct_id>NCT00774124</nct_id>
  </id_info>
  <brief_title>Improving Outcomes in Underserved Women With GDM</brief_title>
  <official_title>Improving Outcomes in Underserved Women With GDM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to test an innovative approach to improve outcomes among underserved women
      with gestational diabetes. We ill utilize a multi-lingual, Interactive Voice Response (IVR)
      -enabled telephone system to facilitate diabetes control and thereby improve pregnancy
      outcomes. Our hypothesis is that Telemonitoring will improve maternal glycemia, thereby
      reducing infant birth weights and leading to improved pregnancy outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a step care design, women will be randomized into standard of care or Telemonitoring.
      In the standard of care group, women will monitor their blood glucose levels four times a
      day, perform fetal movement counting three times a day and also record insulin doses. The
      women will record this information in a logbook, which will be reviewed by the medical team
      at prenatal visits. In the Telemonitoring group, women will receive the standard of care anmd
      will also transmit their blood glucose and fetal movement information to their health care
      providers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maternal blood glucose control</measure>
    <time_frame>3 to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>infant birthweight</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>1 Telemedicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual care plus telemonitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care - women will monitor and record blood glucose levels four times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemonitoring</intervention_name>
    <description>Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week</description>
    <arm_group_label>1 Telemedicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.</description>
    <arm_group_label>2 Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of GDM

          -  33 or less weeks gestation

        Exclusion Criteria:

          -  multiple gestations

          -  history of glucose intolerance outside of pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J Homko, RN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tallahassee Memorial Diabetes Center</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Homko CJ, Santamore WP, Whiteman V, Bower M, Berger P, Geifman-Holtzman O, Bove AA. Use of an internet-based telemedicine system to manage underserved women with gestational diabetes mellitus. Diabetes Technol Ther. 2007 Jun;9(3):297-306.</citation>
    <PMID>17561800</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GDM, pregnancy, macrosomia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

